PAXMEDICA
PaxMedica is a biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Founded in 2018, the company is based in Tarrytown, New York.
PAXMEDICA
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2018-01-01
Address:
Tarrytown, New York, United States
Country:
United States
Website Url:
http://www.paxmedica.com
Total Employee:
1+
Status:
Active
Contact:
650-889-5020
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Content Delivery Network Euro GStatic Google Static Content Wix Visitor Analytics
Similar Organizations
Novelogics Biotechnology
A pre-clinical stage biotech company developing innovative antibody immunotherapies for cancer using a novel “Interceptor” approach.
Current Employees Featured
Stock Details
Official Site Inspections
http://www.paxmedica.com Semrush global rank: 8.05 M Semrush visits lastest month: 379
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "PaxMedica"
About Us - PaxMedica
PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on Autism Spectrum Disorder (ASD). There are no FDA …See details»
PaxMedica - Crunchbase Company Profile & Funding
PaxMedica conducts clinical trials to evaluate the safety, tolerability, and efficacy of suramin in individuals with Autism Spectrum Disorder. Partnerships for Translational Research …See details»
Investors - PaxMedica
PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on Autism Spectrum Disorder (ASD). There are no FDA …See details»
PaxMedica, Inc. (PXMD) Company Profile & Facts - Yahoo Finance
See the company profile for PaxMedica, Inc. (PXMD) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
PaxMedica, Inc. - AnnualReports.com
PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Their lead programs are …See details»
PaxMedica - businessabc.net
Dec 30, 2024 It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company was …See details»
PaxMedica, Inc. - LinkedIn
PaxMedica (OTCQB: PXMD) is a forward-thinking clinical-stage biopharmaceutical company, unwavering in its dedication to advancing innovative therapies for individuals and families …See details»
PaxMedica - Funding, Financials, Valuation & Investors - Crunchbase
PaxMedica is a biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Search Crunchbase. ... How much funding has …See details»
PaxMedica, Inc. Company Profile | Boston, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for PaxMedica, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
PaxMedica Company Profile - Office Locations, Competitors ... - Craft
May 14, 2024 PaxMedica is a clinical-stage biopharmaceutical company developing anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic …See details»
PaxMedica, Inc. (PXMD) Company Profile & Overview - Stock …
4 days ago PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable …See details»
PaxMedica, Inc. Launches Updated Corporate Website at
Dec 14, 2022 One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and …See details»
PaxMedica - A Promising Path in Autism
About PaxMedica PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with …See details»
PaxMedica, Inc. Launches Updated Corporate Website at …
Dec 14, 2022 One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and …See details»
Industry Spotlight: Paxmedica - The BRAIN Foundation
The results of Paxmedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021. PAX-102 (Intranasal Suramin) PaxMedica …See details»
PaxMedica Provides Company Update and Continues to Advance …
May 7, 2024 PaxMedica, Inc. TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing …See details»
PaxeraUltimAI - PaxeraHealth
Automate organization, prioritization and distribution of imaging studies for radiologists. It ensures that cases are presented in an optimal sequence based on urgency, complexity, patient …See details»
Press Releases - PaxMedica
PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Home; About; FOCUS. ... IBN, …See details»
PaxMedica Achieves Key Milestone in the Development of PAX …
Apr 11, 2024 PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in developing cutting-edge, anti-purinergic drug therapies (APT) aimed at addressing a range of challenging ...See details»
PaxMedica - A Promising Path in Autism
The World Health Organization lists suramin, discovered in 1916, and found to be effective against Stage 1 TBR HAT since at least 1920, as a standard of care for Trypanosoma b. …See details»